PT-112 Shows Promise for Heavily Treated Myeloma Patients
Phosplatin Therapeutics‘ investigational medication PT-112 showed promising efficacy…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read morePhosplatin Therapeutics‘ investigational medication PT-112 showed promising efficacy…
The Multiple Myeloma Research Foundation (MMRF) is partnering…
Janssen and Legend Biotech are seeking U.S. approval for…
The U.S. Food and Drug Administration (FDA) has approved…
A new initiative by GlaxoSmithKline (GSK) is seeking…
PF-06863135, a bispecific antibody being developed by Pfizer…